TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Regulus ( (RGLS) ) is now available.
On March 27, 2025, Regulus Therapeutics Inc. announced positive topline results from the fourth cohort of its Phase 1b study of farabursen for ADPKD treatment. The study showed that the 300 mg fixed dose of farabursen effectively halted the growth of total kidney volume (htTKV) and demonstrated a favorable safety profile. The results suggest that farabursen could significantly impact disease progression by limiting cyst growth, and the data supports the selection of this dose for an upcoming Phase 3 trial.
More about Regulus
Regulus Therapeutics Inc. operates in the biotechnology industry, focusing on developing innovative therapies for genetic diseases. The company’s primary product in development is farabursen (RGLS8429), aimed at treating autosomal dominant polycystic kidney disease (ADPKD), with a market focus on addressing unmet medical needs in genetic disorders.
YTD Price Performance: -17.31%
Average Trading Volume: 478,207
Technical Sentiment Signal: Strong Buy
Current Market Cap: $85.45M
For an in-depth examination of RGLS stock, go to TipRanks’ Stock Analysis page.